Welcome! Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Please take a moment to confirm your subscription below so we can ensure these updates reach your inbox.
Confirm Your Subscription Here
The Earnings360 Team
Today's Featured Article Why GRAIL Stock Could Be Biotech's Next Big BreakoutWritten by Bridget Bennett. Published 11/19/2025. 
Key Points - Insider buying is a reliable signal in market pullbacks, offering long-term confidence amid short-term volatility.
- Biotech stock GRAIL is one to watch, with its breakthrough cancer detection technology nearing FDA approval.
- Despite economic concerns, the American Dream is still attainable through long-term investing, saving, and strategic financial choices.
Retail investors are understandably on edge after recent market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we’re still in one of the best times in history to build wealth—if you think long term and stick to time-tested principles. According to Green, this pullback isn’t as severe as it feels. "Just last Wednesday, the Dow hit an all-time high," he said, adding that recent selling pressure reflects valuation concerns and doubts about interest rates rather than a fundamental breakdown. Why the Market Pulled Back Black Friday Alert: Huge Tesla Shift Ahead?
Tesla could be on the verge of its biggest change ever. Insiders are warning of a coming "critical inflection point" that could have ripple effects across the entire stock market.
Do NOT buy or sell Tesla stock during Black Friday week until you see this. Full briefing here. Green attributes the dip to two main concerns. First, investors are reexamining elevated tech and AI valuations, especially as earnings season highlights whether those expectations are justified. Second, inflation readings and slower hiring have dampened hopes that the Fed will cut rates in December. With the central bank emphasizing a "data-dependent" stance, markets are less certain that relief will arrive this year. Why Selling Now Might Be the Wrong Move Instead of trying to predict next week’s moves, Green urges investors to zoom out. He calls himself "a long-term optimist," noting that, historically, markets trend upward. Traders may want to exercise short-term caution. But for long-term investors, these dips can be opportunities to buy high-quality stocks at more attractive prices. Insider Buying Can Point the Way One reliable indicator in volatile times is insider buying. Green suggests that when officers and directors—people with access to nonpublic financial information—are buying shares in their own companies, it’s worth paying attention to their actions. He recommends tracking insider trading activity to see which stocks corporate executives are purchasing, not just selling. While insiders aren’t always right, their moves can be a useful signal when markets are in flux. A Biotech Breakout to Watch: GRAIL One sector Green’s focused on is biotech, where artificial intelligence is helping accelerate drug development and lower costs. He highlighted one company in particular: GRAIL (NASDAQ: GRAL). Spun off from Illumina, GRAIL developed the Galleri Test, which can detect more than 50 types of cancer from a simple blood draw. Green says he’s used the test himself and calls it "a good feeling" to know you’re clear of so many deadly diseases—especially cancers like pancreatic that often go undetected until late stages. With FDA Fast Track status and potential insurance reimbursement ahead, Green sees GRAIL’s roughly $3 billion market cap as just a starting point. The Biotech Risk—and Big Pharma's Appetite Biotech carries risk: most drugs never make it through all three trial phases. Still, large pharmaceutical companies like Merck (NYSE: MRK), Pfizer (NYSE: PFE), and Bristol Myers (NYSE: BMY) are actively acquiring promising small caps to replace expiring patents. Green pointed to Johnson & Johnson (NYSE: JNJ) as a recent example: the company invested in a private prostate cancer drug before it had FDA approval—underscoring how aggressive Big Pharma can be when clinical trials look promising. He thinks biotech is especially compelling now because healthcare is largely recession-resistant. Whether the economy grows or contracts, people still need treatment. For investors seeking steadiness amid volatility, sectors like healthcare, utilities, consumer staples, and food companies tend to offer reliable demand and less drama than high-flying AI names. The American Dream Is Still Possible—But Mindset Matters Despite economic challenges, Green argues the American Dream is far from dead. He wrote The American Dream to counter the growing narrative that it’s out of reach, noting he was surprised to see polls showing nearly 70% of Americans believe it’s no longer attainable. The reality, he says, is that with low-cost investment tools, no-commission trading, and widely available information, building wealth has never been more accessible. The challenge is knowing what to do—and having the discipline to follow through. He breaks it down simply: if a 25-year-old invests $190 per month in an S&P 500 index fund, they could have $1 million by age 65—tax-free in a Roth IRA. No extreme frugality required. "You could eat out, take trips, and still build wealth," Green says—as long as you save and let that money compound. Creative Solutions for Today’s Housing Market Housing may feel out of reach, but Green says it doesn’t have to be. Mortgage rates have doubled and prices are up about 50% since the pandemic—but there are still ways to get in. He shares his personal story of buying two houses with no money down by working directly with motivated sellers and assuming their mortgages—a method known as a "contract for deed." It might not land you the perfect house immediately, but it can help you start building equity sooner. Stay Focused on the Long Game Volatile markets come and go. What matters is how you respond. Whether it’s tracking insider moves, exploring high-upside sectors like biotech, or simply believing in your own capacity to build a financial future, Green’s message is clear: the American Dream is still within reach. You just have to keep your eyes on it—and take the next right step.
| 
